ResMed Valuation Overview

RMD -- USA Stock  

USD 113.83  2.04  1.82%

ResMed holds recent Real Value of $93.3438125 per share. The prevailing price of the company is $113.83. At this time the company appears to be over valued. Macroaxis determines value of ResMed from analyzing the company fundamentals such as Shares Outstanding of 142.74M, Operating Margin of 29.07% and Return On Equity of 15.70% as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Valuation Drivers Correlation
Click cells to compare fundamentals   View All Correlations
ResMed Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    
ResMed Market Cap
ResMed is rated below average in market capitalization category among related companies. Market capitalization of Medical Instruments & Supplies industry is at this time estimated at about 229.87 Billion. ResMed holds roughly 15.5 Billion in market capitalization claiming about 7% of all equities under Medical Instruments & Supplies industry.
Capitalization  Valuation  Total debt  Revenue  Workforce
Horizon     30 Days    Login   to change
ResMed is rated below average in price to sales category among related companies. It is rated below average in five year return category among related companies reporting about  0.27  of Five Year Return per Price to Sales. The ratio of Price to Sales to Five Year Return for ResMed is roughly  3.64 

Current Market Valuation

ResMed Valuation Boundaries

Over Valued
September 23, 2018
Market Value
Real Value
Target Odds
ResMed is not too risky asset. Calculation of real value of ResMed is based on 1 month time horizon. Increasing ResMed time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Valuation Basics

ResMed Enterprise Value Fundamentals

Quick Ratio1.32
Earnings Quarterly Growth8.10%
Revenue Growth12.00%
Payout Ratio64.49%
Enterprise Value To Ebitda22.75
Earnings Growth7.40%
Enterprise Value To Revenue6.61
Additionally take a look at Your Equity Center. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.